



About JZCP

JZCP is a London listed private equity fund which invests in high quality US and European micro cap companies. It receives investment advice from Jordan/Zalaznick Advisers, Inc. ("JZAI"), which works with the existing management of micro cap companies to help build better businesses, create value and deliver strong returns to investors.

Investment Objective

JZCP seeks to create a portfolio of investments in businesses in the United States and Europe, providing a superior overall return comprised of a current yield and significant capital appreciation.

Recent Events

- On 30 July 2013, JZCP invested \$1.9 million to fund the acquisition of a property in Brooklyn, New York.

Historical and Current NAV per Share and Share Price



Company Summary


	Ordinary Shares	Zero Dividend Preference ("ZDP") Shares
Number of Shares	65,018,607	20,707,141
NAV (\$000's) in USD	\$637,993	n/a
NAV per Share in USD	\$9.81	n/a
NAV per Share in GBP	£6.47	n/a
ZDP Value (£000's) in GBP	n/a	£61,200
ZDP Value per Share	n/a	£2.96 ⁽¹⁾
Quoted Market Price (End of Month) in GBP	£4.75	£3.28
Market Capitalization (\$000's) in GBP	£308,838	£67,868
Quoted Market Price (End of Month) in USD	\$7.20 ⁽²⁾	n/a
Market Capitalization (\$000's) in USD	\$468,214 ⁽²⁾	\$102,891 ⁽²⁾
Premium / (Discount) to NAV per Share	(26.6%)	n/a
Premium / (Discount) to ZDP Value per Share	n/a	10.9%
Currency in quotation	GBP	GBP
Ticker	JZCP	JZCN

Top 10 Holdings (Excluding Cash & Equivalents)

	Investment Type	Value \$ ⁽³⁾	% of Total
Safety Insurance Group, Inc.	Listed Equities	61,906	11%
Factor Energia, S.A.	European Investments	57,496	10%
Accutest Holdings, Inc.	US Micro Cap	29,472	5%
Dental Services Group, Inc.	US Micro Cap	28,254	5%
Grupo Ombuds	European Investments	27,624	5%
Amptek, Inc.	US Micro Cap	21,469	4%
TWH Water Treatment Ind, Inc	US Micro Cap	20,565	3%
Healthcare Products Holdings, Inc.	US Micro Cap	20,204	3%
MedPlast Holdings, Inc.	US Micro Cap	18,472	3%
Milestone Aviation Group Limited	US Micro Cap	17,752	3%
Top 10 Holdings (Ex. Cash & Equivalents)		\$303,214	52%
Remaining Holdings (Ex. Cash & Equivalents)		\$284,726	48%
Total Holdings (Ex. Cash & Equivalents)		\$587,940	100%




Summary of Portfolio



Total Private Investments

	Number	Fair Value \$ ⁽³⁾	% to Total
• US Micro Cap	32	294,910	39%
• European Investments	5	114,540	16%
• Mezzanine	3	3,705	1%
• Real Estate	5	47,819	7%
• Other	5	11,119	2%
Total	50	\$473,093	65%




Total Listed Investments (including Cash & Equivalents)

	Number	Fair Value \$ ⁽³⁾	% to Total
• Listed Equities	2	62,685	9%
• Listed Corporate Bonds	2	40,405	5%
• Bank Debt	1	11,757	2%
• Cash		105,537	14%
• UK Treasury Gilts		39,552	5%
Total	5	\$259,936	35%

Total Investments Assets (including Cash & Equivalents)

	Number	Fair Value \$ ⁽³⁾	% to Total
Total	55	\$733,029	100%

Share growth



Contacts

Manager

Jordan/Zalaznick Advisers, Inc.
767 Fifth Avenue
New York, NY 10153

Auditor

Ernst & Young LLP
PO Box 9
Royal Chambers
St. Julian's Avenue
St. Peter Port
Guernsey, GY1 4AF

Registrar

Equiniti Limited.
Aspect House
Spencer Road
Lancing
West Sussex BN99 6ZX

Administrator

Northern Trust International Fund
Administration Services (Guernsey) Limited
Trafalgar Court
Les Banques
St. Peter Port
Guernsey GY1 3QL

If you want more information regarding JZCP, please call Tom Willetts at FTI Consulting at +44 (0)20 7269 7175.

Disclaimer

This Monthly Fact Sheet updates as of 31 July 2013 various information as to JZCP and its investment portfolio available from third parties whilst continuing as of 31 May 2013 the valuations shown above (and as included in the NAV) for Micro-Cap and unquoted Unaffiliated Mezzanine investments as reported in the Interim Management Statement issued 25 June 2013. Before making investment decisions, investors should consider that the value of JZCP's investments, and the income from them, may go down as well as up and is not guaranteed; that the market price for JZCP shares, depending on supply and demand, may trade at a discount to NAV; and that past performance cannot be relied upon as a guide to future performance. Investors should also consult with their own independent financial and tax advisers when making investment decisions. Although issued and approved by JZCP, this Monthly Fact Sheet does not constitute a solicitation or advice to buy or sell any security.

Footnotes

- (1) Represents accreted balance as of 31 July 2013
- (2) Assumes an exchange rate as of 31 July 2013 of \$1.52 to £1.00.
- (3) USD in thousands